GlassScriptPhysician profile
Miranda Henson
NPI 1952013849
$879.04
in general payments reported to CMS, 2019-2025
22 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $313 · 2024: $389 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.52 | 2023-2025 | Rybelsus, Ozempic |
| Medtronic, INC. | $78.08 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Dexcom, INC. | $48.92 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $46.24 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $42.90 | 2023-2024 | Fycompa |
| Nevro Corp. | $41.96 | 2023 | Senza |
| Grifols USA, LLC | $40.36 | 2023-2024 | Gamunex-C |
| Lundbeck LLC | $38.85 | 2023-2024 | Vyepti, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $34.14 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $33.04 | 2024 | Ingrezza |
| Abbott Laboratories | $24.98 | 2023 | Infinity |
| Xeris Pharmaceuticals, INC. | $23.41 | 2024 | Recorlev |
| Radius Health, INC. | $22.94 | 2025 | |
| Neurelis, INC. | $22.64 | 2023 | Valtoco |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $22.50 | 2024 | Briviact |
| Intuity Medical INC | $19.66 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amgen INC. | $19.60 | 2025 | Uplizna |
| Ibsa Pharma INC. | $19.37 | 2023 | Tirosint, Licart |
| Antares Pharma, INC. | $19.14 | 2025 | Xyosted |
| Beta Bionics, INC. | $17.38 | 2024 | Ilet Bionic Pancreas |
| Kyowa Kirin, INC. | $14.77 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.